S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
LON:SN

Smith & Nephew (SN) Share Price, News & Analysis

GBX 991.60
-28.80 (-2.82%)
(As of 03/28/2024 ET)
Today's Range
991
1,016
50-Day Range
1,018.50
1,137.50
52-Week Range
N/A
Volume
4.32 million shs
Average Volume
343,671 shs
Market Capitalization
£8.67 billion
P/E Ratio
4,131.67
Dividend Yield
3.03%
Price Target
GBX 1,349.50

Smith & Nephew MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
36.1% Upside
GBX 1,349.50 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.95
Upright™ Environmental Score
News Sentiment
0.20mentions of Smith & Nephew in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.88 out of 5 stars

SN stock logo

About Smith & Nephew Stock (LON:SN)

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products, including instruments, technologies, and implants to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

SN Stock Price History

SN Stock News Headlines

Smith & Nephew PLC
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Smith & Nephew share price: an overlooked buy on 2023 results?
SNN Jun 2024 20.000 put
SNN Sep 2024 25.000 call
See More Headlines
Receive SN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Smith & Nephew and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Ex-Dividend for 5/22 Dividend
3/28/2024
Dividend Payable
5/22/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
18,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 1,349.50
High Stock Price Target
GBX 1,500
Low Stock Price Target
GBX 1,150
Potential Upside/Downside
+29.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
£263 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£5.55 billion
Cash Flow
GBX 55.85 per share
Book Value
GBX 598 per share

Miscellaneous

Free Float
N/A
Market Cap
£9.12 billion
Optionable
Not Optionable
Beta
0.51
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Deepak S. Nath Ph.D. (Age 52)
    CEO & Director
    Comp: $4.63M
  • Ms. Anne-Francoise Nesmes (Age 53)
    CFO & Executive Director
    Comp: $1.05M
  • Mr. Paul Connolly (Age 56)
    President of Global Operations
  • Mr. Andrew Swift
    Vice President of Investor Relations
  • Ms. Helen Barraclough (Age 44)
    Group General Counsel & Company Secretary
  • Ms. Alison Parkes (Age 51)
    Chief Compliance Officer & Compliance APAC
  • Mr. Joe Metzger
    Senior Vice President of Marketing Services & Communications
  • Mr. Philip G. Cowdy (Age 57)
    Chief Corporate Development & Corporate Affairs Officer
  • Ms. Elga Lohler (Age 56)
    Chief Human Resources Officer
  • Mr. Bradley Cannon (Age 56)
    President of Global Orthopaedics

SN Stock Analysis - Frequently Asked Questions

Should I buy or sell Smith & Nephew stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SN shares.
View SN analyst ratings
or view top-rated stocks.

What is Smith & Nephew's stock price target for 2024?

5 analysts have issued 12-month target prices for Smith & Nephew's shares. Their SN share price targets range from GBX 1,150 to GBX 1,500. On average, they predict the company's stock price to reach GBX 1,349.50 in the next twelve months. This suggests a possible upside of 36.1% from the stock's current price.
View analysts price targets for SN
or view top-rated stocks among Wall Street analysts.

How have SN shares performed in 2024?

Smith & Nephew's stock was trading at GBX 1,078.50 at the beginning of the year. Since then, SN shares have decreased by 8.1% and is now trading at GBX 991.60.
View the best growth stocks for 2024 here
.

How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?

Smith & Nephew declared a dividend on Tuesday, February 27th. Shareholders of record on Thursday, March 28th will be given a dividend of GBX 0.23 per share on Wednesday, May 22nd. This represents a dividend yield of 1.62%. The ex-dividend date of this dividend is Thursday, March 28th. This is an increase from the stock's previous dividend of GBX 0.14. The official announcement can be viewed at this link.
Read our dividend analysis for SN
.

Is Smith & Nephew a good dividend stock?

Smith & Nephew (LON:SN) pays an annual dividend of GBX 30 per share and currently has a dividend yield of 2.83%. The dividend payout ratio is 12,500.00%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for SN.

What other stocks do shareholders of Smith & Nephew own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Smith & Nephew investors own include Imperial Brands (IMB), Smith & Nephew (SNN), Alexion Pharmaceuticals (ALXN), Barclays (BARC), GSK (GSK), Diageo (DGE), Standard Chartered (STAN), Unilever (ULVR), British American Tobacco (BATS) and BHP Group (BHP).

How do I buy shares of Smith & Nephew?

Shares of SN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:SN) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners